Li Guo,1 Li-Qin Zhao,2 Jin-Yu Chen,2 Ming Li2 1Third Department of General Surgery (Breast Armor Surgery), Ezhou Central Hospital, Ezhou City, 436000, People’s Republic of China; 2Department of Oncology, Ezhou Central Hospital, Ezhou City, 436000, People’
Guo L, Zhao LQ, Chen JY, Li M
doaj
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
A. Yu +19 more
semanticscholar +1 more source
Interferon Alfa in the treatment of B-cell chronic lymphocytic leukemia [PDF]
Adolf, D. +10 more
core +1 more source
'A leukin to the future': is low serum interleukin-2 (IL-2) a predictive biomarker for postoperative atrial fibrillation? [PDF]
Quinn CJ, Velasco ES, Wehrens XHT.
europepmc +1 more source
Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy.
W. Liao, Jian-Xin Lin, W. Leonard
semanticscholar +1 more source
Detection of autoantibodies against thyroglobulin, thyroid microsomes, and other soluble antigens with a rational and economical immunoblotting microtechnique [PDF]
Berndt, H. +5 more
core +1 more source
Targeting severe acidity for tumor-activatable Interleukin-2 therapy. [PDF]
Feng Q +13 more
europepmc +1 more source
Interleukin-2: Biology, Design and Application.
Natalia Arenas-Ramirez +2 more
semanticscholar +1 more source
Capicua mediates interleukin-2 withdrawal-induced death of activated CD8<sup>+</sup> T cells. [PDF]
Shi JG +5 more
europepmc +1 more source

